Table 1 Baseline characteristics of study participants
Variable | n (%) | Median (Range) |
|---|---|---|
Male sex | 24 (57.1) | Â |
Diagnosis | Â | Â |
   de novo AML | 17 (40.5) |  |
   ALL | 12 (28.6) |  |
   CML-AP | 2 (4.8) |  |
   MDS overt AML | 10 (23.8) |  |
   PCL | 1 (2.4) |  |
Cytogenetics | Â | Â |
   Intermediate | 17 |  |
   Poor | 22 |  |
ECOG PS | Â | Â |
   0 | 2 (4.8) |  |
   1 | 25 (59.5) |  |
   2 | 7 (16.7) |  |
   3 | 8 (19.0) |  |
Status at allo-HCT | Â | Â |
   Primary refractory/Refractory relapse/Untreated MDS overt AML | 7/32/3 |  |
No. chemo regimens prior allo-HCT | Â | 6 (0-18) |
Time from diagnosis to allo-HCT (days) | Â | 319 (23-3738) |
Marrow blasts at allo-HCT | Â | 26.0 (0.2-100) |
Conditioning regimen | Â | Â |
   Intensified | 9 (21.4) |  |
   Standard | 12 (28.6) |  |
   Reduced-intensity | 7 (16.7) |  |
   Reduced-intensity + cytoreductive chemotherapy | 14 (33.3) |  |
GVHD prophylaxis | Â | Â |
   None | 3 (7.1) |  |
   Calcineurin inhibitor alone | 5 (11.9) |  |
   Calcineurin inhibitor + sMTX | 32 (76.2) |  |
   Calcineurin inhibitor + MMF | 2 (4.8) |  |
Donor (HLA-A, B and DRB1 antigens) | Â | Â |
   Matched related PB/BM | 10/2 |  |
   Mismatched related PB/BM | 3/1 |  |
   Matched unrelated BM | 19 |  |
   Mismatched unrelated BM | 1 |  |
   Umbilical cord blood | 6 |  |